...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: Re: BETonMACE Enrollment
7
Mar 21, 2017 04:22PM
7
Mar 24, 2017 03:15PM
3
Mar 24, 2017 03:34PM
2
Mar 25, 2017 10:41AM
4
Mar 25, 2017 11:14AM
2
Mar 25, 2017 02:27PM
5
Mar 25, 2017 04:07PM
6
Mar 26, 2017 03:01PM
3
Mar 28, 2017 03:07PM
3
Mar 28, 2017 03:26PM
2
Mar 28, 2017 03:39PM
4
Jun 28, 2017 10:37AM
6
Aug 28, 2017 12:56PM
3
Aug 28, 2017 01:57PM
1
Aug 28, 2017 02:16PM
2
Aug 28, 2017 03:09PM
3
Aug 28, 2017 10:05PM
6
Aug 29, 2017 08:00AM
4
Aug 29, 2017 09:29AM
6
Aug 30, 2017 06:18PM
3
Aug 30, 2017 07:30PM
3
Aug 30, 2017 08:17PM
15
Sep 02, 2017 12:03PM
2
Sep 02, 2017 12:45PM
3
Sep 02, 2017 02:06PM
3
Sep 02, 2017 02:21PM
5
Dec 14, 2017 04:51PM
3
Dec 15, 2017 12:32AM
7
Dec 15, 2017 11:40AM
4
Dec 15, 2017 01:00PM
2
Dec 15, 2017 02:25PM
4
Dec 15, 2017 07:33PM
3
Jan 11, 2018 02:40PM
6
Jan 11, 2018 03:01PM
3
Jan 11, 2018 03:29PM
2
Feb 28, 2018 03:21PM
7
Mar 01, 2018 11:38AM
1
Mar 01, 2018 02:17PM
4
Feb 08, 2019 10:07AM
2
Feb 08, 2019 04:50PM

"Note: Some rounding has been done so values above are +/- 0.5 month. Based on above, a crude estimate of cumulative patient years is 4244, which divided by 2400 patients gives 1.77 years (21.2 months) as the average dosing period. However, this is a crude estimate that does not account for patient deaths or patient dropouts; the "wave" approach creates a lot of uncertainty too."

I had some thought provoking private messages with a few folks this afternoon. It got me thinking more about the degree of patient drop outs in BETonMACE. There are always patient drop outs, especially in long clinical trials. Some of it is because patients die, but for most cases it is some kind of non-fatal adverse event that leads to patient voluntary discontinuation/withdrawal of consent or discontinuation at the advisement of the physician. I looked back at a few recent diabetic CVOT studies and the typical range is 20-30% discontinuation. SUSTAIN-6, EXAMINE, EMPA-REG OUTCOMES, CANVASSELIXA. Like I said, some of this is due to patient death. But a majority is for reasons other than death. 

So thinking back to my patient year estimate of 4244......if we shave off 20% due to patient discontinuation, this gives us closer to 3400 patient years. The percentage of discontinuation may be higher too. However, we don't know how long the patient may have been on placebo or study drug before discontinuation. So a straight cut of 20% may be an over or underestimate. Therefore the events per patient years (annual event rate) estimates, such as those that George provided earlier,may be underestimates due to this discontinuation variable.

BDAZ

1
Feb 09, 2019 02:43PM

Feb 09, 2019 03:31PM
3
Feb 09, 2019 03:52PM

Feb 09, 2019 04:14PM
1
Feb 09, 2019 08:00PM
2
Feb 09, 2019 09:12PM
2
Feb 10, 2019 12:33PM
1
Feb 11, 2019 09:05AM
1
Feb 22, 2019 04:10PM
3
Feb 22, 2019 05:31PM
3
Feb 22, 2019 10:59PM
5
Feb 23, 2019 02:33PM
1
Aug 18, 2019 10:29AM
5
Aug 18, 2019 01:02PM
3
Aug 18, 2019 01:47PM
2
Aug 18, 2019 01:57PM
3
Aug 18, 2019 02:26PM
3
Aug 18, 2019 02:28PM
3
Aug 18, 2019 04:41PM
2
Aug 18, 2019 04:59PM
3
Aug 18, 2019 06:54PM
3
Aug 18, 2019 07:04PM
4
Aug 18, 2019 08:24PM
Share
New Message
Please login to post a reply